Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.

Inclusion Criteria: 1. Voluntary participation and agree to all the purposes of the study by signing and dating ICF; 2. Male or female participantes, regardless of race or social class; 3. Participants aged ≥18 and ≤70 years; 4. Bearer dialysis-dependent CKD (hemodialysis and peritoneal dialysis \*); 5. Clinical diagnosis of anemia, characterized as hemoglobin levels \<10g/dL before the start of the study; 6. Adequate dialysis: Kt / V ≥ 1.2 for hemodialysis patients (based on the calculation of Daugirdas II) and ≥ 1.7 for patients on peritoneal dialysis; 7. Adequate iron stores (TSAT\> 20% and serum ferritin\> 100ng/ml) prior to initiation of treatment with erythropoietin. Exclusion Criteria: 1. Participation in clinical trials in the 12 months preceding the survey; 2. Patients with uncontrolled hypertension, with mean above 180/100mmHg and whose requiring hospitalization in the last 6 months; 3. Presence of other causes of anemia than CKD, such as bleeding, hemolysis, pernicious anemia and hemoglobinopathies; 4. Patients who present changes or clinical abnormalities, qualified as interfering changes, such as severe hyperparathyroidism (iPTH\> 1000 pg / mL), severe congestive heart failure (NYHA Class IV), acute myocardial infarction within the last 3 months, or active neoplasia in follow-up, severe liver disease, active infection (leukocyte changes), history of aluminum toxicity or scheduled surgery, pregnancy or lactation; 5. Patients who have a known hypersensitivity to any component of the formulation and to products derived from mammalian cells; 6. Prior therapies with erythropoietin for less than 3 months; 7. Realization transfusion for less than 3 months; 8. Any situation at the discretion of the Principal Investigator interfere with study data.